ArticleFrontiers in immunology2026
Anti-CENP-B polarity divides SLE: divergent clinical-immune phenotypes and distinct treatment responses.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anti-centromere antibody positivity: a spectrum of clinical diagnoses and immunological patterns in a large patient cohort.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-CENP-B antibodies (anti-CENP-B), directed against centromere protein B, are a serological hallmark of limited cutaneous systemic sclerosis (lcSSc) but are only occasionally encountered in systemic lupus erythematosus (SLE). When detected in SLE they may create diagnostic ambiguity. Since autoantibody-defined SLE subsets exhibit distinct phenotypes, delineating the clinical and immunological features of anti-CENP-B-positive disease is essential for precise management. Methods: We retrospectively collected demographic, clinical, laboratory and therapeutic data from 310 SLE patients including 73 anti-CENP-B-positive patients and 237 anti-CENP-B-negative patients. Inter-group differences, correlations, and multivariable logistic regression were performed. Results: Compared with the anti-CENP-B-negative patients, the anti-CENP-B-positive patients were older, less frequently had lupus nephritis (LN), but more often exhibited Raynaud's phenomenon, cardiac, or pleuropulmonary involvement. Serologically, they displayed lower anti-dsDNA, anti-nucleosome and anti-histone antibody levels, reduced C4, yet higher IgA, IgM, and IgG concentrations and expanded CD19 Conclusions: Anti-CENP-B positivity defines a distinct SLE subset characterized by older age at onset, milder renal involvement, Raynaud's phenomenon, and specific humoral alterations; importantly, these patients also show a treatment response that differs significantly from that of the anti-CENP-B-negative group, underscoring the imperative for personalized, precision therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.